The effect of diabetes mellitus on the pharmacokinetics and pharmacodynamics of tuberculosis treatment

Citation: Alfarisi O, Mave V, Gaikwad S, Sahasradubhe T, Ramachandran G, Kumar H, Gupte N, Kulkarni V, Deshmukh S, Atre S, Raskar S, Lokhande R, Barthwal M, Kakrani A, Gupta A, Golub J, Dooley K. The effect of diabetes mellitus on the pharmacokinetics and pharmacodynamics of tuberculosis treatment. Antimicrob Agents Chemother. 2018 Aug 20. pii: AAC.01383-18. doi: 10.1128/AAC.01383-18. [Epub ahead of print]. PMID: 30126955.

Access full article:

https://www.ncbi.nlm.nih.gov/pubmed/30126955

Background

Diabetes mellitus (DM) and tuberculosis (TB) are two common diseases with increasing geographic overlap and clinical interactions. The effect of DM and hemoglobin A1c (HbA1c) values on the pharmacokinetics and pharmacodynamics of anti-TB drugs remains poorly-characterized.

Methods

Newly-diagnosed TB patients with and without DM starting fixed-dose, thrice-weekly treatment underwent sampling for PK assessments (pre-dose, 0.5, 2, 6 hours post-dose) during intensive and continuation phases of treatment. The effect of DM and HbA1c on the maximum concentration (Cmax) of rifampin, isoniazid, and pyrazinamide and the association between drug concentrations and microbiologic and clinical outcomes were assessed.

Results

Of 243 patients, 101 had DM. Univariate analysis showed significant reductions in Cmax of pyrazinamide and isoniazid (but not rifampicin) with DM or increasing HbA1c. After adjusting for age, sex, and weight, DM was associated only with reduced pyrazinamide concentrations [adjusted GMR: 0.74, p=.032]. In adjusted Cox models, female gender (aHR=1.75, p=0.001), lower Xpert smear grade (aHR=1.40, p<0.001) and pyrazinamide Cmax (aHR=0.99, p=0.006) were independent predictors of sputum culture conversion to negative. Higher isoniazid or rifampicin concentrations were associated with faster time to culture conversion in patients with DM only. Pyrazinamide Cmax above the therapeutic target was associated with higher unfavorable outcomes (treatment failure, relapse, death) [OR: 1.92, p=.041].

Conclusion

DM and higher HbA1c increased the risk of not achieving therapeutic targets for pyrazinamide (but not rifampicin or isoniazid). Higher pyrazinamide concentrations, though, were associated with worse microbiologic and clinical outcomes. DM status also appeared to influence PK-PD relationships for isoniazid and rifampicin.

Antimicrobial Agents and Chemotherapy

Categories

CRS
Topics

Clinical Trials

A5329: Interferon –Free Therapy for Chronic Hepatitis C...

A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C...

Read More

P2010: Phase III Study of the Virologic Efficacy and Safety...

IMPAACT 2010 is a Phase III, three-arm, randomized, open-label study of HIV-1-infected pregnant women initiating either a...

Read More

P2001 (DAIDS ID 12026): Evaluating the Pharmacokinetics,...

TB is a major cause of illness and death in women of reproductive age. Pregnant and postpartum women with latent TB are at...

Read More

A5322: Long-Term Follow-up of Older HIV-infected Adults in...

The A5322 protocol is a long-term observational study, with a planned series of analyses of data to be collected from an...

Read More

P1070, Dose-Finding and Pharmacogenetic Study of Efavirenz...

Efavirenz (EFV) is an anti-HIV medicine that is commonly used to treat HIV infection in adults and children older than 3 years...

Read More